Furthermore, a recent report described rare AML cases with both KMT2A rearrangement and KMT2A PTD, where KMT2A rearrangement likely represented the founder clone, further complicating the detection of KMT2A PTD [17]. The gene discussed is KMT2A; the disease is acute myeloid leukemia.